

Primary intervention with mucosal insulin for prevention of type one diabetes in infants at high genetic risk to develop diabetes

Submission date 07/02/2007	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/03/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 28/04/2015	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
<http://www.diabetes-point.org/nav4uk.html>

Study website
<http://www.diabetes-point.org>

Contact information

Type(s)
Scientific

Contact name
Prof Ezio Bonifacio

Contact details
DFG-Center for Regenerative Therapies Dresden
Fetscherstr. 105
Dresden
Germany
01307

Additional identifiers

EudraCT/CTIS number
2005-001621-29

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

80804002

Study information

Scientific Title

Primary intervention with mucosal insulin for prevention of type one diabetes in infants at high genetic risk to develop diabetes

Acronym

Pre-POINT (Primary Oral INsulin Trial)

Study objectives

Oral application of insulin induces a protective immune response for the purpose of vaccination in infants at high risk of developing type one diabetes mellitus (T1DM).

Please note that as of 18/02/2010 this record has been extensively updated.

1. The intranasal arm of this trial has been removed. Italy and Switzerland have been removed from the countries of recruitment, and Canada has been added.
2. The overall trial start and end date were changed from 01/04/2007 and 30/09/2008 to 01/11/2008 and 30/06/2011, respectively.
3. The target number of participants has been reduced to 25.
4. The sponsor and contact information for this trial has changed.

Previous sponsor:

Institute for Diabetes Research at the Paediatric Clinic (Institut für Diabetesforschung an der Kinderklinik)

Munich Technical University (Technische Universität München)

Kölner Platz 1

Munich (München)

Germany

Previous contact:

Prof Anette-G Ziegler

On 09/07/2013 the overall trial end date was changed from 30/06/2011 to 31/12/2013.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Ethics committee of the Bayrische Landesärztekammer, ref: 05135
2. Ethikkommission der Mediz. Univ. Wien (ref: 341/2007), NHS National Research Ethics Service, ref: 10/H0106/33, COMIRB (05-1043)

Study design

Randomised placebo-controlled double-blind/double-masked multi-centre dose-escalation primary intervention pilot study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Type 1 diabetes-associated development of autoimmunity

Interventions

Current information as of 18/02/2010:

Active arm: insulin given orally at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg daily

Control arm: placebo administered orally

Initial information at time of registration:

Active arm A: insulin given orally at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg daily

Active arm B: insulin given intra-nasally at 0.28 mg, 0.83 mg, 2.5 mg, or 7.5 mg daily for ten days and twice weekly thereafter

Control arm A: placebo administered orally

Control arm B: placebo administered intra-nasally

Children will be treated for the duration of the Pre-POINT study or until becoming Glutamic Acid Decarboxylase (GAD) or IA-2 auto-antibody positive or until diabetes onset. Average expected duration of treatment: 11 months (minimum three months; maximum 18 months corresponding to expected Pre-POINT study duration).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Insulin

Primary outcome measure

The development of immunity to insulin (Immunoglobulin G [IgG] or Immunoglobulin A [IgA] antibodies, or T-cell response to insulin and/or insulin peptides).

Secondary outcome measures

1. Safety and bioavailability of mucosal insulin
2. Determination of an appropriate route and dose for insulin

Overall study start date

01/11/2008

Completion date

31/12/2013

Eligibility

Key inclusion criteria

Current inclusion criteria as of 09/07/2013:

1. Children aged 2 to 7 years who:

1.1. Have a multiplex first degree family history of T1DM (both parents, parent and siblings, or two siblings) and a type 1 diabetes susceptible Human Leukocyte Antigen (HLA) DR4-DQB1*0302 or DR4-DQB1*0304 haplotype and none of the following HLA DR or DQB1 alleles:

1.1.1 DR 11

1.1.2 DR 12

1.1.3 DQB1*0602

1.1.4 DR7-DQB1*0303

1.1.5 DR14-DQB1*0503

1.2. Have a sibling with T1DM and are identical by descent for the HLA DR3/DR4-DQ8 genotype with their diabetic sibling

2. Islet auto-antibody (IA-2) negative at time of recruitment

Previous inclusion criteria:

1. Children aged 2 to 7 years who:

1.1. Have a multiplex first degree family history of T1DM (both parents, parent and siblings, or two siblings) and have one of the following Human Leukocyte Antigen (HLA) genotypes:

1.1.1. DR4- DQA1*0301-DQB1*0302 / DR3- DQA1*0501-DQB1*0201

1.1.2. DR4- DQA1*0301-DQB1*0302 / DR4- DQA1*0301-DQB1*0302

1.1.3. DR4- DQA1*0301-DQB1*0302 / DR4- DQA1*0301-DQB1*0201

1.1.4. DR4- DQA1*0301-DQB1*0302 / DR4- DQA1*0301-DQB1*0304, or

1.2. Have a sibling with T1DM and are identical by descent for the HLA DR3/DR4-DQ8 genotype with their diabetic sibling

2. Islet auto-antibody (IA-2) negative at time of recruitment

Participant type(s)

Patient

Age group

Child

Lower age limit

2 Years

Upper age limit

7 Years

Sex

Both

Target number of participants

25

Key exclusion criteria

1. Children with any kind of congenital or acquired chronic disease that potentially interfere with the study objectives
2. Prior or current participation in another intervention trial

Date of first enrolment

01/11/2008

Date of final enrolment

31/12/2013

Locations**Countries of recruitment**

Austria

Germany

Italy

Switzerland

United Kingdom

United States of America

Study participating centre

DFG-Center for Regenerative Therapies Dresden

Dresden

Germany

01307

Sponsor information**Organisation**

Medical Faculty Carl Gustav Carus (Germany)

Sponsor details

Dresden University of Technology

Fetscherstr. 74

Dresden

Germany

01307

Sponsor type

University/education

Website

http://tu-dresden.de/die_tu_dresden/fakultaeten/medizinische_fakultaet/index_html/document_view?cl=en

ROR

<https://ror.org/04za5zm41>

Funder(s)

Funder type

Charity

Funder Name

Juvenile Diabetes Research Foundation (JDRF) (USA)

Funder Name

German Federal Ministry of Education and Research (Bundesministerium Für Bildung und Forschung [BMBF]) (Germany)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	21/04/2015		Yes	No
HRA research summary			28/06/2023	No	No